Patents by Inventor Seung-Suh Hong

Seung-Suh Hong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10703802
    Abstract: The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 7, 2020
    Assignee: CELLTRION, INC.
    Inventors: Seung Suh Hong, Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Sung Hwan Kim, Eun Beom Lee, Jae Won Lee, So Jung Lee, Ji Young Shin, Myung Sam Cho
  • Patent number: 10507240
    Abstract: The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: December 17, 2019
    Assignee: CELLTRION, Inc.
    Inventors: Joon Sun Yoon, Hwa Jin Lee, Kye Sook Yi, Cheol Min Kim, Byung Pil Lim, Shin Jae Chang, Seung Suh Hong
  • Patent number: 10239902
    Abstract: The present invention provides a stable peptide-conjugated, ascorbic acid derivative, a method for preparing the same, and a cosmetic composition comprising the same as an active ingredient. The stable peptide-conjugated ascorbic acid derivative of the present invention has both the effect of whitening the skin by inhibiting melanin production and the effect of reducing skin wrinkles by activating collagen production, and may be used in a cosmetic composition.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: March 26, 2019
    Assignee: CELLTRION INC.
    Inventors: Young Jun Park, Jung Yun Kim, Jin Kyo Jeong, Hyeong Mi Kim, Eun Joo Cho, Joo Hyuck Lim, Hyun Nam Song, Seon Kyung Park, Won Kang Moon, Shin Jae Chang, Seung Suh Hong
  • Publication number: 20170326231
    Abstract: The present invention relates to an epitope specific to hepatitis B virus surface antigen and a binding molecule binding to the same for neutralizing hepatitis B virus. Since the epitope provided by the present invention is produced by forming a three-dimensional structure and does not comprise a determinant, by which escape mutation is induced against an administration of existing vaccines or HBIg, a composition comprising an antibody biding to the epitope or a vaccine composition comprising the epitope has a very low possibility of causing a decrease in efficacy due to escape mutation. Therefore, such an antibody or vaccine composition can be very effectively used in prevention and/or treatment of HBV.
    Type: Application
    Filed: November 27, 2015
    Publication date: November 16, 2017
    Applicant: CELLTRION, INC.
    Inventors: Joon Sun Yoon, Hwa Jin Lee, Kye Sook Yi, Cheol Min Kim, Byung Pil Lim, Shin Jae Chang, Seung Suh Hong
  • Patent number: 9814784
    Abstract: The present invention relates to an antibody-linker-drug conjugate in which an antibody and a cytotoxic drug are conjugated through an enzyme cleavable peptide linker capable of directly binding to a lysine residue of an antibody, a preparation method therefor, and an anticancer drug composition containing the same as an active ingredient.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: November 14, 2017
    Assignee: CELLTRION, INC.
    Inventors: Young Jun Park, Jin-kyo Jeong, Young Mi Choi, Minseob Lee, Yeon Jung Kim, Kyoung Suk Kim, Joon hun Choi, Jin Seo Lee, Eun Joo Cho, Hyunnam Song, Sung Jun Park, Jong-hyoup Lee, Matthew Sangyup Lee, In-Suk Lee, Joon woo Kim, Seung Suh Hong
  • Publication number: 20170258931
    Abstract: The present invention provides a stable peptide-conjugated, ascorbic acid derivative, a method for preparing the same, and a cosmetic composition comprising the same as an active ingredient. The stable peptide-conjugated ascorbic acid derivative of the present invention has both the effect of whitening the skin by inhibiting melanin production and the effect of reducing skin wrinkles by activating collagen production, and may be used in a cosmetic composition.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Applicant: CELLTRION INC.
    Inventors: Young Jun Park, Jung Yun Kim, Jin Kyo Jeong, Hyeong Mi Kim, Eun Joo Cho, Joo Hyuck Lim, Hyun Nam Song, Seon Kyung Park, Won Kang Moon, Shin Jae Chang, Seung Suh Hong
  • Patent number: 9278996
    Abstract: The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: March 8, 2016
    Assignee: CELLTRION, INC.
    Inventors: Young Jun Park, Jin-kyo Jeong, Young Mi Choi, Min Seob Lee, Joon hun Choi, Eun Joo Cho, Hyunnam Song, Sung Jun Park, Jong-hyoup Lee, Seung Suh Hong
  • Publication number: 20160052997
    Abstract: The present invention provides a composition comprising at least two influenza A virus-neutralizing binding molecules that bind to an epitope in the stem region of influenza A virus hemagglutinin (HA) protein, the method comprising: i) a first binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H2, H5 and H9; ii) a second binding molecule capable of neutralizing at least one influenza A virus subtype selected from the group consisting of H1, H3, H5, H7 and H9. The mixed composition of the present invention can effectively neutralize the multiple influenza subtypes of both phylogenetic group 1 and phylogenetic group 2 and can be used in combination with a chemical compound. Thus, the composition of the present invention is very useful for the prevention and treatment of a disease by influenza virus.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 25, 2016
    Inventors: Seung Suh HONG, Shin Jae CHANG, Ki Sung KWON, Kye Sook YI, Sung Hwan KIM, Eun Beom LEE, Jae Won LEE, So Jung LEE, Ji Young SHIN, Myung Sam CHO
  • Publication number: 20150366990
    Abstract: The present invention relates to an antibody-linker-drug conjugate in which an antibody and a cytotoxic drug are conjugated through an enzyme cleavable peptide linker capable of directly binding to a lysine residue of an antibody, a preparation method therefor, and an anticancer drug composition containing the same as an active ingredient.
    Type: Application
    Filed: January 2, 2014
    Publication date: December 24, 2015
    Inventors: Young Jun PARK, Jin-kyo JEONG, Young Mi CHOI, Minseob LEE, Yeon Jung KIM, Kyoung Suk KIM, Joon hun CHOI, Jin Seo LEE, Eun Joo CHO, Hyunnam SONG, Sung Jun PARK, Jong-hyoup LEE, Matthew Sangyup LEE, In-Suk LEE, Joon woo KIN, Seung Suh HONG
  • Publication number: 20150225455
    Abstract: The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient.
    Type: Application
    Filed: September 16, 2013
    Publication date: August 13, 2015
    Applicant: CELLTRION, INC.
    Inventors: Young Jun Park, Jin-kyo Jeong, Young Mi Choi, Min Seob Lee, Joon hun Choi, Eun Joo Cho, Hyunnam Song, Sung Jun Park, Jong-hyoup Lee, Seung Suh Hong
  • Patent number: 8772021
    Abstract: Provided are an expression vector for an animal cell including a promoter, a cloning site or a polynucleotide encoding foreign product, and a transcription terminator, all of which are operably connected each other within the expression vector, in which at least one copy of human ?-globin MAR sequence is attached to the 31 terminal of the transcription terminator, and a method of expressing a foreign gene using the expression vector.
    Type: Grant
    Filed: March 4, 2006
    Date of Patent: July 8, 2014
    Assignee: Celltrion, Inc.
    Inventors: Jong-mook Kim, Hye-jin Hong, Hyun-joo Lee, Moon-kyoung So, Soo-young Lee, Jong-moon Cho, Bok-hwan Chun, Seung-suh Hong, Myung-sam Cho
  • Publication number: 20080102523
    Abstract: Provided are an expression vector for an animal cell including a promoter, a cloning site or a polynucleotide encoding foreign product, and a transcription terminator, all of which are operably connected each other within the expression vector, in which at least one copy of human ?-globin MAR sequence is attached to the 3? terminal of the transcription terminator, and a method of expressing a foreign gene using the expression vector.
    Type: Application
    Filed: March 4, 2006
    Publication date: May 1, 2008
    Applicant: CELLTRION, INC.
    Inventors: Jong-mook Kim, Hye-jin Hong, Hyun-joo Lee, Moon-kyoung So, Soo-young Lee, Jong-moon Cho, Bok-hwan Chun, Seung-suh Hong, Myung-sam Cho
  • Patent number: 6987002
    Abstract: The present invention relates to a composition for detecting an infinitesimal quantity of ?-1,3-glucan, a preparation method thereof and a diagnostic kit detecting ?-1,3-glucan. The composition of the present invention shows phenoloxidase activity by ?-1,3-glucan in the presence of calcium ions. Using the composition of the present invention, a sample is gathered from a specimen, the composition of the present invention and calcium ions are added to the sample, and ?-1,3-glucan is detected by measuring phenoloxidase activity.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: January 17, 2006
    Assignee: Samyang Genex Corporation
    Inventors: Joong Hyuck Auh, Bu Soo Park, Chang Hun Joo, Chong Jin Park, Bok Luel Lee, Kum Young Lee, Seung-Suh Hong, Hyun-Soo Lee
  • Patent number: 6713611
    Abstract: The present invention relates to a method of removing an endotoxin from solution containing basic proteins. More specifically, the method of the present invention comprises the steps of adding the surfactant to solution containing the basic protein obtained from the recombinant microorganism and mixing the resultant, of loading the resultant solution on the cation exchange column, washing the cation exchange column with solution which does not contain surfactant, and eluting the basic protein of interest from the cation exchange column.
    Type: Grant
    Filed: September 6, 2001
    Date of Patent: March 30, 2004
    Assignee: Samyang Genex Co.
    Inventors: Sang-Hyun Pyo, Heung-Bok Park, Jin-Eon So, Jin-Hyun Kim, Seung-Suh Hong, Hyun-Soo Lee
  • Patent number: 6699689
    Abstract: The present invention relates to DNA constructs that can produce antimicrobial materials efficiently from microorganisms and the preparation method thereof. The present invention also relates to the useful vector for the DNA construct. The DNA construct according to the present invention comprises a first gene coding for entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide. According to the present invention, antimicrobial peptides can be mass-produced by the following steps: preparing an expression vector containing a DNA construct comprising a first gene coding for an entire, a part of or a derivative of purF gene and a second gene coding for antimicrobial peptide; transforming the bacterial host cells with the above-mentioned vector, culturing the transformed cell to express the above-mentioned DNA construct; and recovering the above antimicrobial peptide.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: March 2, 2004
    Assignee: Samyang Genex Corporation
    Inventors: Jeong Hyun Kim, Min Hyung Kang, Jae Hyun Lee, Se Ho Park, Joo Won Lee, Seung Suh Hong, Hyun Soo Lee
  • Publication number: 20030143203
    Abstract: The present invention relates to recombinant adenoviruses expressing interleukin-18 protein, and gene therapy using them. More particularly, the invention provides recombinant adenoviruses Ad.promIL-18, Ad.GMmIL-18, Ad.prohIL-18, Ad.hIL-18CPP32- and Ad.preprotrypsin.hIL-18CPP32- which are effectively capable of treating a variety of cancer cells by promoting and enhancing an immune response in vivo.
    Type: Application
    Filed: March 22, 2002
    Publication date: July 31, 2003
    Inventors: Dong-Soo Im, Won-Kyung Cho, Kyung-Sun Hwang, Young-Rim Seong, Seung-Suh Hong
  • Patent number: 6589765
    Abstract: The present invention relate to a method to increase the production level of paclitaxel by changing the temperature during the plant cell culture. According to the present invention, the production of the paclitaxel comprises the following procedure: (i) cultivating the Taxus genus plant cells in a medium at ca. 20 to 25° C.; and (ii) when growth of the plant cells has progressed sufficiently, changing the cultivation temperature to ca. 26 to 32° C. to continue the culture. The present invention comprises also the method of increasing the paclitaxel production by inoculating the cells at a high initial concentration and by increasing the saccharide concentration in the medium: According to the present invention, paclitaxel can be mass-produced conveniently and therefore has an industrial application.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: July 8, 2003
    Assignee: Samyang Genex Corporation
    Inventors: Ho-Joon Choi, Hyung-Kyoon Choi, Sang-Ic Kim, Jeong-Hwan Yun, Joo-Sun Son, Moon-Seok Chang, Eunsoo Choi, Hong-Rak Kim, Seung-Suh Hong, Hyun-Soo Lee
  • Patent number: 6573371
    Abstract: The present invention relates to a diagnosis method of cancer using SYG972 gene and to the genomic DNA and to a promoter regulating transcription of the gene. Expression of SYG972 gene is greatly reduced in breast cancer cells compared to normal breast cells. Therefore the present invention provides a method of diagnosis method by using the gene of the present invention or its fragments as a probe. SYG972 genomic according to the present invention is composed of 4 exons and 3 introns. Promoter is 3 kb long from the transcription initiating site in the 5′ direction. SYG972 genomic DNA and promoter can be used to design and screen drugs to promote or to inhibit apoptosis and differentiation of cells, especially to screen drugs to treat cancer, a disease wherein cell growth and differentiation is abnormal.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: June 3, 2003
    Assignee: Samyang Genex Corporation
    Inventors: Neon-Cheol Jung, Jin-Man Kim, Seung-Suh Hong, Hyun-Soo Lee, Young-Rim Seong, Jae-Ho Lee
  • Patent number: 6531446
    Abstract: The present invention relates to peptides that are more potent than or equally potent as the conventional antimicrobial peptides and has strong antimicrobial activities at high salt concentration.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: March 11, 2003
    Assignee: Korea Advanced Institute of Science and Technology
    Inventors: Sun-Chang Kim, Chan-Bae Park, Jae-Hyun Lee, Seung-Suh Hong, Hyun-Soo Lee
  • Publication number: 20030007964
    Abstract: The present invention relates to a novel use of histone and an active fragment thereof and provides a pharmaceutical composition containing histone as an active ingredient to improve the symptoms of progressive, inflammatory and autoimmune arthritis. The pharmaceutical composition of the present invention includes histone, especially histone H1, histone H2A, histone H2B, histone H3, histone H4, an active fragment thereof, and a mixture thereof as an active ingredient, and could include pharmacologically approved carriers if necessary. Histone or its active fragment lowered induction of arthritis and reduced arthritis index more effectively than steroidal dexamethasone and also had a significant preventive effect.
    Type: Application
    Filed: June 12, 2002
    Publication date: January 9, 2003
    Applicant: SAMYANG GENEX CORPORATION
    Inventors: Insoo Bae, Dong-soo Kim, Heajoon Yim, Neon-Cheol Jung, Yong-Weon Yi, Seung-Suh Hong, Hyun-Soo Lee